- Home
- RNAZ vs CELZ Comparison
RNAZ vs CELZ Comparison
Compare RNAZ & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- CELZ
- Stock Information
- Founded
- RNAZ 2016
- CELZ 1998
- Country
- RNAZ United States
- CELZ United States
- Employees
- RNAZ N/A
- CELZ N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- CELZ Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- CELZ Health Care
- Exchange
- RNAZ Nasdaq
- CELZ Nasdaq
- Market Cap
- RNAZ 4.9M
- CELZ 4.7M
- IPO Year
- RNAZ 2021
- CELZ N/A
- Fundamental
- Price
- RNAZ $3.84
- CELZ $2.26
- Analyst Decision
- RNAZ Strong Buy
- CELZ
- Analyst Count
- RNAZ 1
- CELZ 0
- Target Price
- RNAZ $99.00
- CELZ N/A
- AVG Volume (30 Days)
- RNAZ 30.4K
- CELZ 23.0K
- Earning Date
- RNAZ 11-14-2024
- CELZ 11-08-2024
- Dividend Yield
- RNAZ N/A
- CELZ N/A
- EPS Growth
- RNAZ N/A
- CELZ N/A
- EPS
- RNAZ N/A
- CELZ N/A
- Revenue
- RNAZ N/A
- CELZ $11,000.00
- Revenue This Year
- RNAZ N/A
- CELZ N/A
- Revenue Next Year
- RNAZ $233.33
- CELZ N/A
- P/E Ratio
- RNAZ N/A
- CELZ N/A
- Revenue Growth
- RNAZ N/A
- CELZ N/A
- 52 Week Low
- RNAZ $6.31
- CELZ $2.12
- 52 Week High
- RNAZ $264.00
- CELZ $10.28
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.15
- CELZ 35.64
- Support Level
- RNAZ $6.63
- CELZ $2.12
- Resistance Level
- RNAZ $8.46
- CELZ $2.50
- Average True Range (ATR)
- RNAZ 1.04
- CELZ 0.19
- MACD
- RNAZ -0.25
- CELZ 0.02
- Stochastic Oscillator
- RNAZ 1.65
- CELZ 26.55
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.